Drug Trial Radar · NCT04924101
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
122
Actual
Start
Jul 15, 2021
Primary completion
Jun 23, 2025
Study completion Jun 23, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jun 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the first-line treatment of participants with extensive-stage small cell Lung Cancer (ES-SCLC). No formal hypothesis testing will be performed for this study.
Conditions
- Small Cell Lung Cancer
Interventions
PembrolizumabBiological
IV infusion
MK-4830Biological
IV infusion
BoserolimabBiological
IV infusion
LenvatinibDrug
Oral capsule
EtoposideDrug
IV infusion
CisplatinDrug
IV infusion
CarboplatinDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)Time frame: Up to approximately 43 months
- Six-Month Progression-Free Survival (PFS) Rate as Assessed by BICR Per RECIST 1.1Time frame: At 6 months
Locations
49 sites in 11 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center ( Site 0102)
Gilbert, Arizona
University of Colorado Anschutz Medical Campus ( Site 0104)
Aurora, Colorado
Georgia Cancer Specialists ( Site 0106)
Atlanta, Georgia
Parkview Research Center at Parkview Regional Medical Center ( Site 0130)
Fort Wayne, Indiana
Baptist Health Lexington-Research ( Site 0108)
Lexington, Kentucky
MFSMC-HJWCI-Oncology Research ( Site 0128)
Baltimore, Maryland
Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0122)
Omaha, Nebraska
Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0129)
Omaha, Nebraska
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0114)
Mineola, New York
Memorial Sloan Kettering Cancer Center ( Site 0115)
New York, New York
Cleveland Clinic-Taussig Cancer Center ( Site 0116)
Cleveland, Ohio
UPMC Hillman Cancer Center ( Site 0127)
Pittsburgh, Pennsylvania
St Francis Cancer Center-Research Office ( Site 0117)
Greenville, South Carolina
Virginia Cancer Institute ( Site 0119)
Richmond, Virginia
Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 2100)
Vienna, Austria
Klinik Penzing-2. Lungenabteilung ( Site 2101)
Vienna, State of Vienna, Austria
Hamilton Health Sciences-Juravinski Cancer Centre ( Site 2003)
Hamilton, Ontario, Canada
Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 2005)
Kingston, Ontario, Canada
St. Marys Hospital Center ( Site 2000)
Montreal, Quebec, Canada
Semmelweis University-Pulmonológiai Klinika ( Site 2802)
Budapest, Hungary
Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Onkologiai Kozpont ( Site 2800)
Szolnok, Jász-Nagykun-Szolnok, Hungary
Országos Korányi Pulmonológiai Intézet-XIV. Tüdöbelgyógyászat ( Site 2806)
Budapest, Pest County, Hungary
Torokbalint Tudogyogyintezet-Onkopulmonologiai Jarobeteg Centrum ( Site 2801)
Törökbálint, Pest County, Hungary
Zala Megyei Szent Rafael Kórház-Pulmonológia ( Site 2805)
Zalaegerszeg, Zala County, Hungary
Rambam Health Care Campus-Oncology ( Site 2600)
Haifa, Israel
Shaare Zedek Medical Center ( Site 2602)
Jerusalem, Israel
Meir Medical Center ( Site 2601)
Kfar Saba, Israel
Rabin Medical Center-Oncology ( Site 2604)
Petah Tikva, Israel
Sheba Medical Center-ONCOLOGY ( Site 2603)
Ramat Gan, Israel
Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Toracica ( Site 2304)
Milan, Italy
Ospedale San Raffaele-Oncologia Medica ( Site 2303)
Milan, Lombardy, Italy
ospedale le scotte-U.O.C. Immunoterapia Oncologica ( Site 2300)
Siena, Tuscany, Italy
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier
Warsaw, Masovian Voivodeship, Poland
Samodzielny Publiczny Zespó Grulicy i Chorób Puc w Olsztynie-Oddzial Onkologii z Pododdzialem Chemi
Olsztyn, Warmian-Masurian Voivodeship, Poland
Scientific research institution of oncology named after N.N. Petrov-Thoracic oncology ( Site 2704)
Saint Petersburg, Russia
Krasnoyarsk Regional Oncology Dispensary, Named after Krizhanovsky ( Site 2708)
Krasnoyarsk, Krasnoyarsk Krai, Russia
GBUZ "SPb CRPCstmc(o)" ( Site 2705)
Saint Petersburg, Sankt-Peterburg, Russia
N.N.Petrov Research Institute of Oncology-Department of Chemotherapy and Innovative Technologies ( S
Saint Petersburg, Sankt-Peterburg, Russia
Seoul National University Hospital ( Site 1101)
Seoul, South Korea
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1105)
Seoul, South Korea
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.